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Purpose: To evaluate the clinical results of proton beam radiation therapy (PBRT) for treatment of retinoblastoma.
Methods: Children with retinoblastoma who were treated with chemotherapy and focal treatment such as brachy-
therapy and thermotherapy but showed no response or developed recurrences later received PBRT. The PBRT 
strategy was designed to concentrate the radiation energy to the retinoblastoma and spare the surrounding 
healthy tissue or organs.
Results: There were three patients who received PBRT. The first patient received PBRT because of an initial lack of 
tumor regression with chemotherapy and brachytherapy. This patient showed regression after PBRT. The sec-
ond patient who developed recurrence of retinoblastoma as diffuse infiltrating subretinal seeding was taken 
PBRT. After complete regression, there was recurrence of tumor and the eye was enucleated. The third patient 
had unilateral extensively advanced retinoblastoma. Initial chemotherapy failed and tumor recurred. The tumor 
responded to PBRT and regressed significantly. However, the eye developed sudden multiple recurrences, so 
we had to perform enucleation.
Conclusions: PBRT for retinoblastoma was effective in cases of showing no response to other treatment modalities. 
However, it should be carefully applied when there was recurrence of diffuse infiltrating subretinal seeding or ex-
tensively advanced retinoblastoma initially.
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 Retinoblastoma is the most common primary intraocular 
malignancy in childhood. The incidence is estimated at 
about 1 in 15,000 to 20,000 live births [1,2]. Since the first 
retinoblastoma patient was successfully treated with radia-
tion therapy [3], due to the radiosensitive nature of retino-
blastoma [4], external beam radiation therapy (EBRT) has 
been thought to be the first line and major treatment method 
for retinoblastoma. However, there is a very high incidence 
of secondary malignant neoplasm among the survivors of 
heritable retinoblastoma [5-7], as well as cosmetic problems 
of orbital bone growth retardation in those who received 
EBRT, particularly in younger children [8]. Therefore, treat-
ment modalities were shifted toward primary systemic chemo-
therapy for reducing tumor volume initially (chemoreduction) 
and additional focal treatment such as cryotherapy, thermo-
therapy, or brachytherapy [9]. These latter methods increased 
the salvage rate of globes and reduced complications of 
EBRT [10]. However, those methods cannot replace all the 
area of EBRT for retinoblastoma.
There has been substantial advancement in radiation therapy 
techniques, including recently developed intensity-modulated 
radiotherapy, stereotactic conformal radiotherapy and proton 
beam radiation therapy (PBRT). Among these, PBRT is the Korean J Ophthalmol Vol.25, No.6, 2011
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most recently developed and has proved to be the superior ra-
diation therapy technique, providing a greater radiation dose 
to the target tumor with increased sparing of normal adjacent 
structures. Lee et al. [11] compared these three radiation 
techniques for the treatment of retinoblastoma, medullo-
blastoma, and pelvic sarcoma. Including this report, there are 
a few papers that analyzed the advantages of PBRT for reti-
noblastoma with regard to radiation distribution, but these 
lack clinical results after treatment [11-13]. 
Here, we present clinical courses of three challenging cas-
es of retinoblastoma which were managed with PBRT.
Materials and Methods 
Patient selection
Three retinoblastoma patients who were diagnosed and 
treated with chemotherapy and focal treatment in Seoul 
National University Children’s Hospital and received PBRT 
at the Proton Therapy Center, National Cancer Center (NCC) 
in Korea between June 2007 and August 2009 were selected 
for this retrospective study.
The eligibility criteria for inclusion were children with 
newly diagnosed intraocular retinoblastoma who were initially 
treated with chemotherapy and focal treatment but showed 
no response to these strategies from the beginning or who 
showed favorable response at first but developed recurrence 
of the tumor during or after the treatment. Treatment was 
therefore followed by PBRT.
Exclusion criteria included eyes considered to be danger-
ous without immediate enucleation and eyes that exhibited 
severe vitreal or subretinal seeding or displayed evidence of 
tumor invasion into the anterior segment, choroid, optic 
nerve or extraocular tissue following clinical examination, 
ultrasonography and neuroimaging methods.
We performed two combination regimens of chemotherapy. 
One consisted of cisplatin, etoposide, doxorubicin, cyclo-
phosphamide and vincristine and the other was a combina-
tion of carboplatin, etoposide and vincristine. Every cycle 
was repeated each month for one week for a total of 6 to 13 
cycles, according to patient condition and tumor status. 
Examination under anesthesia was done before every cycle 
of chemotherapy and fundus photos were taken using a 
RetCam II (Clarity Medical System, Pleasanton, CA, USA). 
Thermotherapy was performed if possible when tumor vol-
ume was considerably reduced to allow focal treatment with 
the Oculight SLX diode laser (Iridex Corp., Mountain 
View, CA, USA). If there was no response to chemotherapy 
initially or if recurrence developed after chemotherapy and 
focal treatment, then we referred the patient to NCC for 
PBRT.
Proton beam radiation therapy 
A plane computed tomography (CT) scan was taken with a 
2-mm slice along the orbital space with or without an eye ro-
tation using a suction cup, depending on the tumor locations. 
Gross tumor volumes (GTVs), clinical target volumes (CTVs), 
and planning target volumes (PTVs) were delineated. PTV 
was CTV + 2 mm, and CTV was designed to cover any retina 
posterior to the equator with the intent to prevent the devel-
opment of new foci. Critical structures, such as the ipsilateral 
lens, orbital bone and soft tissues, optic nerve, lacrimal 
gland, contralateral eye, temporal and frontal lobes, and pi-
tuitary gland, were delineated as organs at risk (OARs). 
Proton beam planning was performed using a three-dimen-
sional treatment-planning system (Eclipse proton planning 
system ver. 8.1.2; Varian Medical System, Palo Alto, CA, 
USA) and dose distributions were determined for each target 
volume and OARs. Three-dimensional proton plans were 
performed to give PTV 95% of the prescribed dose. The pre-
scribed doses were 46 cobalt grey equivalents (CGE; CGE = 
proton Gy x relative biological effectiveness 1.1) to PTV for 
two patients and 50 CGE to PTV for the one patient who had 
a large tumor with subretinal tumor seeding. For proton beam 
planning, the proximal and distal margins for targets were 3 
mm, respectively, and the border smoothing and smearing 
margins were set to 0.5 and 1.2 mm, respectively. A smearing 
margin of 1.2 mm was given to allow the margin for setup 
uncertainty. The block margins were set to 5 mm. For all pa-
tients, a single beam was used in the gantry room to treat the 
macroscopic GTV and the microscopic CTV. To achieve 
maximum dose conformity, all beams were customized to the 
target, with brass apertures and Lucite compensators fab-
ricated by a computer-driven milling machine, to specifica-
tions from the planning program. 
During the principal treatment setup, the patient was in the 
supine position under propofol-based total intravenous 
anesthesia. For each patient, a thermoplastic mask was 
fabricated. Daily eye setup and treatment field positioning 
were checked using the laser beams in relation to the suction 
cup centered on the cornea. The radiopaque wires built into 
the silicon suction cup served as an auxiliary marker to the 
patient’s bony anatomy. For every patient, anatomy-based 
clinical setup was performed and then double-checked using 
a comparison between the digitally reconstructed radiograph 
obtained from the plane CT scan and X-rays (digital image 
positioning system) taken in the treatment room. 
Results
Case 1
A 4-year-old boy was referred with sporadic bilateral ocu-
lar retinoblastoma. In the right eye, we observed International 
Classification of Retinoblastoma (ICRB) group E, Reese- 
Ellsworth Classification (R-E) group V retinoblastoma, oc-
cupying the entire globe. In the left eye, ICRB group B, R-E 
group IV, a retinoblastoma larger than 8 DD size mass was 
situated anterior to the equator without subretinal or vitreous JW Chang, et al. Proton Beam Radiation Therapy for Retinoblastoma
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Fig. 1. (A) There was no significant change in the tumor size and shape af-
ter chemotherapy and brachytherapy. Therefore, we started proton beam 
radiation therapy (PBRT). (B) Proton dose distribution of an anterior me-
dially oriented oblique beam with the eye rotated in the temporal direction. 
Radiation was concentrated to the nasal side of the tumor but there was 
minimal radiation distribution to surrounding normal tissue. (C) Complete
regression of the tumor after PBRT. 
seeding. After the immediate primary enucleation of the right 
eye, chemotherapy with cisplatin, etoposide, doxorubicin, 
cyclophosphamide and vincristine was initiated and the biop-
sy results showed choroid and optic nerve invasion over the 
lamina cribrosa but resection margin was clear. Before the 
third cycle of chemotherapy, we observed an increase in size 
of the retinoblastoma in the left eye and topotecan was added 
to the original chemotherapy regimen. After one cycle of the 
new regimen, the tumor continued to grow. Brachytherapy 
with I-125 was performed but there was no change in tumor 
size for six months then we decided to perform PBRT (Fig. 1A).
PBRT with total dose of 46 Gy delivered in 23 fractions 
was performed (Fig. 1B). One month after the end of PBRT, 
the tumor started to shrink, and two months later had de-
creased further, allowing us to perform thermotherapy with 
diode laser. After additional thermotherapy, six months after 
the end of PBRT, the tumor had regressed completely (Fig. 1C). 
Case 2
A 1-year-old girl without any family history of retino-
blastoma visited for evaluation of left leukocoria. There were 
multiple tumors around the optic disc and macula with sub-
retinal seeding classified as ICRB group D, R-E group II in 
right eye and large peripapillary endophytic mass with total 
retinal detachment classified as ICRB group B, R-E group V 
in left eye. Chemotherapy with cisplatin, etoposide, doxor-
ubicin, cyclophosphamide and vincristine was initiated, 
which led to the regression of multiple tumors, the reattach-
ment of the retina and complete regression finally. Despite 
the application of thermotherapy to the subretinal seeding 
area, the lesion grew and new lesions of subretinal seeding 
inferior to the macula developed. We had to consider EBRT 
in that case and decided to perform PBRT, considering her age.
PBRT, with total dose of 46 Gy delivered in 23 fractions, 
was performed (Fig. 2C). One month after completion of 
PBRT, the subretinal seeding had regressed completely (Fig. 
2D and 2E). The patient was tumor-free for seven months. 
However, vitreous hemorrhage was observed at routine ex-
amination under anesthesia after eight months of PBRT. We 
closely observed the patient and found newly developed 
small mass developed at the area of previously regressed sub-
retinal seeding. The mass have grown rapidly to near the op-
tic nerve during three months, so we carefully decided to 
enucleate the eye. Pathology result of the enucleated eye 
showed dysplastic retina with dystrophic calcification, con-
sistent with near complete necrosis of tumor without invasion 
of choroid, anterior chamber, sclera and lamina cribrosa.
Case 3 
A 5-year-old boy was presented with left leukocoria. There Korean J Ophthalmol Vol.25, No.6, 2011
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Fig. 2. (A,B) Subretinal seeding developed after 
completion of chemotherapy. (C) Proton dose 
distribution of a right posterior oblique beam with
the eye straight position. Radiation covered whole
retina behind the lens and there was no radiation 
distribution to contralateral eye. (D,E) One month
after proton beam radiation therapy, there was 
complete regression of subretinal seeding. 
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was sporadic unilateral ICRB group E, R-E group V, massive 
retinoblastoma with diffuse subretinal seeding and total reti-
nal detachment around huge mass in the left eye (Fig. 3A). 
Chemotherapy with carboplatin, etoposide and vincristine 
was started and one cycle of chemotherapy led to reattach-
ment of retina and significant shrinkage of tumor volume 
with reduced subretinal seeding. But before starting third cy-
cle of chemotherapy there was recurrence of diffuse sub-
retinal seeding especially around optic disc (Fig. 3B). Instead 
of enucleation, which was refused by the patient’s parents, 
we performed PBRT.
PBRT, with total dose of 50.4 Gy delivered in 28 fractions, 
was performed (Fig. 3C). At the end of PBRT, all subretinal 
seeding had disappeared around the optic disc and peripheral 
retina with further reduced volume of the original tumor (Fig. 3D). 
However, three weeks later, during the examination before 
the planned thermotherapy to treat the residual tumor, an in-
creased volume of the retinoblastoma and multifocal re-
currence at the area around the tumor and around almost the 
entire ora serrata were discovered (Fig. 3E). We decided to 
perform enucleation carefully after consultation with radia-
tion oncologist and pediatric oncologist. Pathology report de-JW Chang, et al. Proton Beam Radiation Therapy for Retinoblastoma
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Fig. 3. (A) There was massive tumor with total reti-
nal detachment and peripheral subretinal seeding at in-
itial presentation. (B) Newly developed diffuse sub-
retinal seeding around the tumor and optic disc during 
chemotherapy. (C) Proton dose distribution of a lat-
eral beam orientation with the eye in a straight 
position. The maximum energy of radiation cov-
ered the entire retina including proximal optic 
nerve. (D) There was total regression of subretinal 
seeding and significant shrinkage of the main tumor
after proton beam radiation therapy (PBRT). (E) 
Three weeks after PBRT, the main tumor increased 
and multiple tumor reoccurrences developed 
around the tumor and at the entire ora serrata. We per-
formed enucleation. 
C
D  E
scribed there were tumor involvement of about 40% of retina 
containing 5% necrosis without invasion of choroid, sclera 
and lamina cribrosa.
Discussion
The proton is one of the components of atomic nuclei, as 
discovered by Ernest Rutherford in 1919. Later in 1946, 
Robert Wilson was the first one who suggested its applica-
tion for medical treatment [14]. Since then, several efforts 
have been made to treat tumors using PBRT [16-18] and in 
1992, Croughs et al. [18] reported the first treatment results 
for PBRT in three retinoblastoma patients. 
 The major benefits of the PBRT are 1) coverage of the tar-
get zone with a uniform dose, 2) a zero dose deep to that tar-
get for each beam path, 3) a lower dose proximal to the target 
[19]. Protons can penetrate tissue toward the target tumor 
with less energy loss, give uniform radiation to targeted tu-
mor and finally distribute no energy beyond the target. These 
unique properties of protons can reduce the incidence of sev-
eral side effects of radiation therapy in retinoblastoma in-
cluding late occurrence of secondary malignant neoplasm, Korean J Ophthalmol Vol.25, No.6, 2011
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retardation of tissue growth and atrophic or degenerative 
changes to the tissue. 
The most important goal of treatment for pediatric retino-
blastoma is to save the life of the child. The next priority is to 
save the eyeball and vision. The introduction of chemo-
therapy could have satisfied both purposes. Since the time 
when Kingston et al. [9] established the current regimen of 
chemotherapy, it has been used to reduce tumor volume and 
make additional focal therapy possible. Using these treat-
ment modalities have not only much improved the ocular sal-
vage rates [10,20] but also have reduced the occurrence of 
secondary malignant tumors and intracranial neuroblastic tu-
mors, such as pinealoblastoma [21]. 
Despite the effectiveness of chemotherapy, even in cases 
of initial total tumor regression with chemoreduction fol-
lowed by focal treatment, subretinal and vitreous seeds recur 
[22,23]. In one series, the incidence of recurrent vitreous 
seeds among those who initially presented was about 50% at 
five years; the incidence of recurrent subretinal seeds at five 
years was about 62% [23]. These conditions should be man-
aged promptly and the treatment plans could be various focal 
treatments if seeding were localized. If the seeding is ex-
tensive, it should be managed with EBRT or enucleation. In 
fact, EBRT should be the only way to save the eye in that case.
We presented undesirable circumstances that any oph-
thalmic oncologist may meet during the management of 
retinoblastoma. In case 1, the patient presented with sporadic 
bilateral retinoblastoma and required enucleation of one eye 
due to the extensive size of the tumor. Unfortunately, the tu-
mor resisted not only various chemotherapy regimens but al-
so brachytherapy using I-125. EBRT had to be considered. 
Instead of EBRT, we consider PBRT and it had successively 
controlled the tumor so that we could save the eye while try-
ing to minimize patient suffering due to the occurrence of 
secondary malignant neoplasm or facial deformity, which 
may be induced by EBRT. In case 2, also with sporadic bi-
lateral retinoblastoma, the originally discovered multiple tu-
mors responded well with chemotherapy and additional 
thermotherapy. Even though multifocal recurrence of the tu-
mor developed during chemotherapy, those were treated well 
with thermotherapy. However, after completing the thirteen 
cycles of chemotherapy, a large area of subretinal seeding 
developed. We tried focal consolidation with diode laser but 
subretinal seeding was advanced. PBRT made it disappear 
completely. In case 3, the large sporadic unilateral retino-
blastoma, which was presented later than in the other two 
children, was accompanied by peripheral extensive sub-
retinal seeding. Furthermore, total retinal detachment made 
us consider primary enucleation. However, the parents stout-
ly refused this option, so we started chemotherapy as a sec-
ond option. The tumor seemed to respond well to chemo-
therapy at first but during the early period of chemotherapy, 
diffuse subretinal seeding surrounding the optic disc developed. 
We were afraid of local invasion through the optic disc. 
Therefore, instead of enucleation, we proceeded with PBRT 
and the result was favorable; complete resolution of sub-
retinal seeding with quite reduced tumor volume was seen, 
allowing additional thermotherapy. But three weeks after the 
completion of PBRT, we obtained unexpected results. Not 
only did the main tumor grow significantly, but multifocal re-
currences also developed around the tumor and at the ora 
serrata. We had to perform enucleation in the end.
Considering the differences between the two cases of fa-
vorable results and the last devastating case, the latter in-
volved disseminated subretinal seeding at presentation, ante-
rior to the equator, with massive tumor. Even if seeding ap-
peared to have disappeared after two cycles of chemo-
therapy, as Wilson et al. [22] suggested, tumor cells could ex-
ist in vitreous or avascular subretinal spaces that the chemo-
therapy could not reach. EBRT is the treatment of choice for 
diffuse subretinal and vitreous seeding when systemic che-
motherapy has failed. Although the ocular survival rate in ad-
vanced retinoblastoma (R-E group Vb) is about 50% with 
EBRT, the results are not promising [24]. Similar to the case 
presented here, the original tumor mass grows and multiple 
tumor recurrences develop around the main mass despite 
PBRT. That means the tumor had characteristics of resistance 
not only to chemotherapy agents but also to radiation. 
Another consideration in this case was the fact that multiple 
recurrent tumor foci located near the ora serrata might be re-
lated to the method of radiation distribution for sparing 
lenses. The more anterior part, from equator to ora serrata, 
was involved in the radiation field where higher cataracts de-
veloped [25]. To avoid the development of cataracts, the pos-
terior part of the ora serrata was excluded from the radiation 
field so there were higher recurrence rates at the anterior reti-
na, especially the ora serrata, as observed in this case. 
In conclusion, PBRT was a effective initially in cases of 
late recurrence, such as diffuse subretinal seeding after com-
pletion of chemotherapy or no response to chemoreduction 
with additional focal treatment including brachytherapy. 
However, as the case 2 and 3 demonstrate, even when retino-
blastoma seemed to respond to PBRT, it could recur after a 
few months. Therefore, we need to observe patients who re-
ceived PBRT and demonstrated favorable results for longer 
periods of time, because the tumor-free period of the patients 
in this study averaged about nine months. And the theoret-
ically proposed advantages of PBRT, which were the lower 
occurrence of secondary malignant neoplasm or facial de-
formity, should be confirmed and bolstered by additional 
long-term follow-up studies.
Conflict of Interest
No potential conflict of interest relevant to this article was 
reported.
References
  1.Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol JW Chang, et al. Proton Beam Radiation Therapy for Retinoblastoma
393
1975;80:263-5.
  2.Tamboli A, Podgor MJ, Horm JW. The incidence of retino-
blastoma in the United States: 1974 through 1985. Arch 
Ophthalmol 1990;108:128-32.
  3.Verhoeff FH. Glioma retinae treated by X-rays, with apparent 
destruction of the tumor and preservation of normal vision. 
Trans Am Ophthalmol Soc 1921;19:209-16.
  4.Hilgartner HL. Report of case of double glioma treated with 
x-ray. 1903. Tex Med 2005;101:10.
  5.Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence 
after retinoblastoma. Radiation dose and sarcoma risk. JAMA 
1997;278:1262-7. 
    6.Mohney BG, Robertson DM, Schomberg PJ, Hodge DO. 
Second nonocular tumors in survivors of heritable retino-
blastoma and prior radiation therapy. Am J Ophthalmol 1998; 
126:269-77.
  7.Smith LM, Donaldson SS, Egbert PR, et al. Aggressive man-
agement of second primary tumors in survivors of hereditary 
retinoblastoma. Int J Radiat Oncol Biol Phys 1989;17:499-505.
  8.Imhof SM, Mourits MP, Hofman P, et al. Quantification of or-
bital and mid-facial growth retardation after megavoltage ex-
ternal beam irradiation in children with retinoblastoma. 
Ophthalmology 1996;103:263-8. 
  9.Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. 
Results of combined chemotherapy and radiotherapy for ad-
vanced intraocular retinoblastoma. Arch Ophthalmol 1996; 
114:1339-43. 
10.Shields CL, Shields JA, Needle M, et al. Combined chemo-
reduction and adjuvant treatment for intraocular retinoblastoma. 
Ophthalmology 1997;104:2101-11. 
11. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning 
with protons for pediatric retinoblastoma, medulloblastoma, 
and pelvic sarcoma: how do protons compare with other con-
formal techniques? Int J Radiat Oncol Biol Phys 2005;63: 
362-72. 
12. Krengli M, Hug EB, Adams JA, et al. Proton radiation therapy 
for retinoblastoma: comparison of various intraocular tumor 
locations and beam arrangements. Int J Radiat Oncol Biol 
Phys 2005;61:583-93.
13. Munier FL, Verwey J, Pica A, et al. New developments in ex-
ternal beam radiotherapy for retinoblastoma: from lens to nor-
mal tissue-sparing techniques. Clin Experiment Ophthalmol 
2008;36:78-89.
14.Crowther JG. The cavendish laboratory 1874-1974. New 
York: Science History Publication; 1974. p. 181.
15.Debus J, Hug EB, Liebsch NJ, et al. Brainstem tolerance to 
conformal radiotherapy of skull base tumors. Int J Radiat 
Oncol Biol Phys 1997;39:967-75.
16.Egger E, Schalenbourg A, Zografos L, et al. Maximizing local 
tumor control and survival after proton beam radiotherapy of 
uveal melanoma. Int J Radiat Oncol Biol Phys 2001;51: 
138-47.
17.Bush DA, Slater JD, Bonnet R, et al. Proton-beam radio-
therapy for early-stage lung cancer. Chest 1999;116:1313-9.
18.Croughs P, Deman C, Richard F, et al. Treatment of retino-
blastoma using accelerated protons. Bull Soc Belge Ophtalmol 
1992;243:81-5.
19.Suit H. The Gray Lecture 2001: coming technical advances in 
radiation oncology. Int J Radiat Oncol Biol Phys 2002;53: 
798-809.
20.Gunduz K, Shields CL, Shields JA, et al. The outcome of che-
moreduction treatment in patients with Reese-Ellsworth group 
V retinoblastoma. Arch Ophthalmol 1998;116:1613-7. 
21.Shields CL, Meadows AT, Shields JA, et al. Chemoreduction 
for retinoblastoma may prevent intracranial neuroblastic ma-
lignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 
119:1269-72.
22.Wilson MW, Rodriguez-Galindo C, Haik BG, et al. Multiagent 
chemotherapy as neoadjuvant treatment for multifocal intra-
ocular retinoblastoma. Ophthalmology 2001;108:2106-14.
23.Shields CL, Honavar SG, Shields JA, et al. Factors predictive 
of recurrence of retinal tumors, vitreous seeds, and subretinal 
seeds following chemoreduction for retinoblastoma. Arch 
Ophthalmol 2002;120:460-4.
24.Abramson DH, Beaverson KL, Chang ST, et al. Outcome fol-
lowing initial external beam radiotherapy in patients with 
Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol 
2004;122:1316-23.
25.Fontanesi J, Pratt CB, Kun LE, et al. Treatment outcome and 
dose-response relationship in infants younger than 1 year 
treated for retinoblastoma with primary irradiation. Med 
Pediatr Oncol 1996;26:297-304.